CClinicalTrials.gg
CompletedNCT04929522Updated Oct 7, 2021Results posted

Success Rate of 4 Injection Protocols for Mandibular First Molars With Symptomatic Irreversible Pulpitis

An interventional study of local anesthesia in Root Canal Infection, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 21 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-07.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2021, registered Jun 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
21 Years to 49 Years
Sex
All
01

Study summary

Achieving profound anesthesia during endodontic treatment of mandibular molars with symptomatic irreversible pulpitis is still a demanding clinical challenge. therefore, the success Rate of 4 Injection protocols for Mandibular First Molars with Symptomatic Irreversible Pulpitis was evaluated clinically in a randomized triple-blind trial

Read the detailed description

Trial design This study was a prospective, randomized, parallel, triple blinded, clinical trial. The present trial design methodology conforms to the CONSORT guidelines for reporting randomized clinical trials.Participants A sample size calculation was performed based on the study by (Kanaa M, Whitworth JM, Meechan JG. A Prospective Randomized Trial of Different Supplementary Local Anesthetic Techniques after Failure of Inferior Alveolar Nerve Block in Patients with Irreversible Pulpitis in Mandibular Teeth. J Endod 2012;38:421-425). This research was based on a type I error of 0.05 and a power of 0.8 and indicated that ideally a sample size of 36 in each group would be required to detect a 20% difference in the success rate of the test groups. To increase the validity of the study, 40 subjects in each group were considered.Ethical considerations This trial was conducted with the approval of the institutional review of board (IRB) of the ethics committee at the Faculty of Dentistry, Ain Shams University, Cairo, Egypt (FDASU-REC 772019). Patients signed a printed informed consent form after explanation of the treatment procedure and associated possible adverse effects of the proposed interventions such as discomfort, pain, anesthetic failure and systemic side effects at this stage. Randomization To ensure random selection, participants were allocated randomly into four groups with1:1 allocation ratio by using computer generated randomization (www.randome.org). The sequence was therefore generated.

Allocation concealment mechanism: The sequentially generated numbers were placed in opaque envelopes until the intervention was conducted, and each participant was asked to select an envelope that determines which group of intervention was assumed.

Implementation: Co-researcher used computer generated randomization for participants who achieve eligibility criteria and accordingly participants were enrolled in either of the groups under study.

Blinding Both the participants, the operator who initiated endodontic treatment and monitored the pain, and the statistician were blinded to the anesthetic techniques used.

Intervention Diagnosis was confirmed through history reporting spontaneous pain, a moderate to severe painful response that persists after thermal stimulation, a prolonged response to cold testing with Endo-Ice (1,1,1,2 tetrafluoroethane; Hygenic Corp, Akron, OH), absence of percussion sensitivity and the periapical aspect of the tooth in the bidimensional periapical radiograph was normal. Matching vital contralateral teeth were also tested to ensure an accurate diagnosis and to serve as controls. To prevent bias, this diagnostic step was performed by one investigator (AH), while another investigator (DK) was responsible for administration of all anesthetic injections (DK), and a third investigator (SS) was responsible for root canal treatment procedures and pain recording. All investigators have a minimum of 12 years of clinical experience in endodontics.

One hundred and eighty-five patients consecutively visited were assessed for eligibility. Twenty-five patients were excluded for different reasons and the others (eighty-four female and seventy-six male patients) were allocated to the trial (Figure 1) and randomly assigned into 4 groups (n=40) as follows:

Group 1 (IANB): After determining the injection site and aspiration, 3.6ml of the anesthetic solution was administered using the standard inferior alveolar nerve block (IANB), this was considered the control group.

Group 2 (IANB + IO): A standard IANB was administered the same as for Group 1, followed by a supplemental intraosseous infusion (IO) injection using the Anesto system (W\&H Dentalwerk Bürmoos, Austria). To ensure comfort during the procedure, 0.1ml of anesthetic solution was infiltrated at the perforation site using the standard syringe. The perforation site was selected near the junction of the attached and unattached gingival tissues, immediately distal to the first molar. Perforation was accomplished by operating the Anesto handpiece at full speed, with constant moderate pressure maintained until the perforator was felt to 'drop' into the cancellous bone. 1.8mL of the anesthetic solution was then deposited over a 60-second period. The Anesto handpiece was again retracted and, with the perforator rotating, removed from the injection site.

Group 3 (IANB + PDL): A standard IANB was administered the same as for groups 1 and 3, followed by a supplemental periodontal ligament (PDL) injection. The needle was wedged with force into the PDL space between the tooth and the alveolar crest of the bone, at 30-degrees to the long axis of the tooth. The thumb and index fingers of the left hand supported the needle to prevent buckling. The handle of the syringe was squeezed firmly until backpressure was achieved. Then a total of 1.8ml of the anesthetic solution were injected mesially and distally to the treated molar.

Group 4 (IANB + BI): A standard IANB was administered the same as for groups 1, 2 and 3, followed by a supplemental buccal infiltration at the buccal side of the affected tooth. A total of 1.8ml of the anesthetic solution were injected halfway the mesiodistal width of the clinical crown.

IANB, PDL and BI injections were performed with a conventional dental syringe (indicate the brand) and a 27-G needle at a rate of 2 mL/min. The anesthetic solution used for all techniques was Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain). The efficacy of anesthesia was determined by the following: (1) confirmation of lip numbness, (2) negative response to Endo-Ice, (3) negative response to the maximum output of the electric pulp tester (Parkell, Edgewood, NY, USA).

Root canal treatment procedure was later initiated, and the patients were asked to rate their pain using a visual analogue scale (VAS). Pain was scored as follows: Score 0, no pain; Score 1, mild pain; Score 2, moderate pain; or Score 3, severe pain. After rubber dam placement and during caries removal, access preparation and pulpectomy, success of the anesthetic technique was determined by VAS. The technique was considered as a 'success' when the patient reported no pain (VAS = 0 or 1) and as a 'failure' otherwise (VAS >1).

Heart rate changes were monitored with a finger pulse oximeter (Medlinket, Shenzhen Med-link Electronics, Shenzhen, China). It was recorded from 2 min before to 5 min after injection, at 30-s intervals. The mean heart rate for each injection was recorded.

Statistical analysis All analyses were undertaken with IBM SPSS Statistics (SPSS 26.0; SPSS Inc., Chicago, IL). The anesthetic success rates were analyzed using the chi-square test. Age differences were analyzed using One Way ANOVA, gender differences were analyzed using the Fischer Exact test while heart rate changes were analysed with Kruskal Wallis test, being non-normally distributed. Statistically significant differences were set at the P \< 0.05 level

02

Conditions studied

  • Root Canal Infection

Browse trials for

Keywords

  • intra-osseous injection
  • PDL injection
  • IANB
03

In context

Pulpitis

301 studies on the registry are indexed under Pulpitis; 66 are open to participants now.

This study's enrollment of 160 is above the median of 63 across 274 interventional studies indexed under Pulpitis.

Browse Pulpitis studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,879 studies on the registry; 424 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients included in the study were healthy males and females
  • (Category: American Society of Anesthesiologists class 1)
  • aged 21-49 years
  • with no physical disability, facial paresthesia or psychological problems
  • presenting with a single vital mature mandibular first molar, with signs and/or symptoms of symptomatic irreversible pulpitis

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • patients who took analgesics or other medications that would alter the inflammatory response of the pulp or provide analgesia 6- hours pre-operatively
  • those with known sensitivity to the pharmaceuticals used in this trial.
  • those with pathological periodontal pockets
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Active comparator
    IANB/inferior alveolar nerve block

    patients will be given standard IANB with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).

    Procedure: local anesthesia

  • Active comparator
    IANB+IO

    patients will be given standard IANB plus an intra-osseous with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).

    Procedure: local anesthesia

  • Active comparator
    IANB+PDL

    patients will be given standard IANB plus a PDL injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).

    Procedure: local anesthesia

  • Active comparator
    IANB+BI

    patients will be given standard IANB plus a BI injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).

    Procedure: local anesthesia

Interventions

  • Procedurelocal anesthesia

    technique for local anesthesia

06

What researchers measure

Primary outcomes

  1. Number of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)

    the patients were asked to rate their pain using a Verbal rating scale (VRS). Pain was scored as follows: Score 0, no pain; Score 1, mild pain; Score 2, moderate pain; or Score 3, severe pain. After rubber dam placement and during caries removal, access preparation and pulpectomy, success of the anesthetic technique was determined by NRS. The technique was considered as a 'success' when the patient reported no pain (VRS = 0 or 1) and as a 'failure' otherwise (vRS \>1).

    Time frame: 15 minutes from delivery of anesthesia

Secondary outcomes

  1. Changes in the Heart Rate Before, During and After the Injection

    beat per minute measured by a finger pulse oximeter

    Time frame: assessed from 2 min before to 5 min after injection (at 30-s intervals)

07

Results

Posted Oct 7, 2021

Participant flow

Participant flow — Overall Study
MilestoneIANB/Inferior Alveolar Nerve BlockIANB+IOIANB+PDLIANB+BI
Started40404040
Completed40404040
Not completed0000

Outcome measures

PrimaryNumber of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)

the patients were asked to rate their pain using a Verbal rating scale (VRS). Pain was scored as follows: Score 0, no pain; Score 1, mild pain; Score 2, moderate pain; or Score 3, severe pain. After rubber dam placement and during caries removal, access preparation and pulpectomy, success of the anesthetic technique was determined by NRS. The technique was considered as a 'success' when the patient reported no pain (VRS = 0 or 1) and as a 'failure' otherwise (vRS \>1).

Time frame:
15 minutes from delivery of anesthesia
Reported as:
Count of participants · Participants
Number of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)
ParticipantsIANB/Inferior Alveolar Nerve BlockIANB+IOIANB+PDLIANB+BI
Number of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)16372926
SecondaryChanges in the Heart Rate Before, During and After the Injection

beat per minute measured by a finger pulse oximeter

Time frame:
assessed from 2 min before to 5 min after injection (at 30-s intervals)
Reported as:
Mean · beat per minutes
Changes in the Heart Rate Before, During and After the Injection
beat per minutesIANB/Inferior Alveolar Nerve BlockIANB+IOIANB+PDLIANB+BI
-2 minutes72 ± 472 ± 571 ± 471 ± 5
-1.5 minutes71 ± 472 ± 570 ± 469 ± 4
-1 minute71 ± 571 ± 471 ± 570 ± 4
-0.5 minute72 ± 572 ± 572 ± 471 ± 3
0 minutes75 ± 680 ± 774 ± 572 ± 5
0.5 minute76 ± 485 ± 575 ± 672 ± 4
1 minute74 ± 584 ± 673 ± 471 ± 4
1.5 minutes74 ± 583 ± 773 ± 571 ± 4
2 minutes72 ± 480 ± 672 ± 571 ± 4
2.5 minutes72 ± 477 ± 572 ± 370 ± 4
3 minutes71 ± 374 ± 472 ± 471 ± 2
3.5 minutes72 ± 372 ± 472 ± 471 ± 3
4 minutes72 ± 471 ± 371 ± 372 ± 3
4.5 minutes71 ± 472 ± 371 ± 371 ± 2
5 minutes71 ± 371 ± 271 ± 172 ± 3

Adverse events

Collected over from 2 min before to 5 min after injection, at 30-s intervals.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IANB/Inferior Alveolar Nerve Block0/40 (0%)0/40 (0%)0/40 (0%)
IANB+IO0/40 (0%)0/40 (0%)0/40 (0%)
IANB+PDL0/40 (0%)0/40 (0%)0/40 (0%)
IANB+BI0/40 (0%)0/40 (0%)0/40 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IANB/Inferior Alveolar Nerve BlockIANB+IOIANB+PDLIANB+BITotal
<=18 years00000
Between 18 and 65 years40404040160
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)IANB/Inferior Alveolar Nerve BlockIANB+IOIANB+PDLIANB+BITotal
Female25282623102
Male1512141758
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)IANB/Inferior Alveolar Nerve BlockIANB+IOIANB+PDLIANB+BITotal
Count of participants————0
Region of Enrollment
Region of Enrollment(participants)IANB/Inferior Alveolar Nerve BlockIANB+IOIANB+PDLIANB+BITotal
Egypt40404040160
08

Study locations

1 site
  • Ain Shams University
    Cairo, Egypt
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Oct 5, 2021

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04929522
Lead sponsor
Ain Shams University
Responsible party
Shehab El Din Mohamed Saber (Professor, Ain Shams University) — Principal investigator
First posted
Jun 18, 2021
Start date
Jan 1, 2021
Primary completion
May 30, 2021
Completion
May 30, 2021
Results posted
Oct 7, 2021
Last update
Oct 7, 2021

Study contacts

Ahmed Abdel Rahman Hashem
study director · Ain Shams University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion